Metformin modulates alveolar bone parameters and gene expression in streptozotocin-induced type 2 diabetic rats
4 affiliations
- 1Oral Biology Department, Faculty of Dentistry, Cairo University, Cairo, Egypt
- 2Stem Cells and Tissue Engineering Research Group, Faculty of Dentistry, Cairo University, Cairo, Egypt
- 3Department of Basic Dental Sciences, Faculty of Dentistry, University of Science and Technology, Aden, Yemen
- 4Department of Oral and Maxillofacial Radiology, Faculty of Dentistry, Cairo University, Cairo, Egypt
Abstract
Background Diabetes mellitus (DM) is linked with defective bone healing and metabolic disturbances that increase fracture risk. Although metformin (MET) is used traditionally as first-line treatment for type 2 diabetes (T2DM), its effectiveness in completely reversing diabetic bone homeostasis is uncertain. The present study was conducted to assess the short-term effect of MET on alveolar bone histological structure and osteoblastic gene expression in rats with streptozotocin (STZ)-induced type 2 diabetes mellitus (T2DM). Methods Eighteen adult male Wistar rats were divided equally into three groups (n = 6/group): control group (non-diabetic) was injected with saline, STZ group (diabetic) received 10% fructose solution for 2 weeks followed by an injection of a single dose of STZ (40 mg/kg), and MET group (diabetic with MET-treatment) received 100 mg/kg/day MET for 30 days. Alveolar bone was assessed by histological and histomorphometric analysis, cone beam computed tomography (CBCT), and reverse transcription-polymerase chain reaction (RT-PCR) analysis of bone-related gene expression. Results The STZ group showed pronounced decreases in total bone area, osteoblast area, and bone-related gene expression (RunX2, osteocalcin, COL1A1) compared to the control group. MET significantly improved these parameters compared to the STZ group. Conclusions Metformin significantly increased total bone area and osteoblastic gene expression (Runx2, osteocalcin, and COL1A1) compared to untreated diabetic rats but did not fully restore them to control (non-diabetic) levels. These results suggest a partial protective effect of metformin in alveolar bone in this short-term T2DM rat model.
Related
- Effects of Metformin Treatment on Liver Glucose Metabolism-Related Enzyme Levels in Streptozotocin-Induced Diabetic Rats
- Effect of Carvacrol on PI3K/Akt Signaling, GLUT2 and Insulin Expression in Pancreatic Tissue in a Streptozotocin-Induced Type 1 Diabetic Rat Model
- Effects of high-intensity treadmill exercise on GLUT4, TNF-α, and INSIG1 mRNA expression and blood glucose levels in streptozotocin-induced diabetic rats
- Metformin reduces the proliferation of prostate and liver cancer cell lines and alters the expression of DKK1 and GADD45A
- KH1 Domain of Poly C Binding Protein 1 (PCBP1) Interacts with Utrophin-A mRNA and Modulates Utrophin-A Expression in Mouse Myoblasts
BibTeX
@article{radwan2026metformin,
title = {{Metformin modulates alveolar bone parameters and gene expression in streptozotocin-induced type 2 diabetic rats}},
author = {Israa Ahmed Radwan and Gamilah Al-Qadhi and Hanaa S. Mansy and Sana Mostafa and Sara El Moshy},
journal = {BMC Oral Health},
year = {2026},
month = nov,
doi = {10.1186/s12903-026-10091-1},
url = {https://doi.org/10.1186/s12903-026-10091-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metformin modulates alveolar bone parameters and gene expression in streptozotocin-induced type 2 diabetic rats
AU - Israa Ahmed Radwan
AU - Gamilah Al-Qadhi
AU - Hanaa S. Mansy
AU - Sana Mostafa
AU - Sara El Moshy
PY - 2026
DA - 2026/11/05
JO - BMC Oral Health
DO - 10.1186/s12903-026-10091-1
UR - https://doi.org/10.1186/s12903-026-10091-1
AB - Background Diabetes mellitus (DM) is linked with defective bone healing and metabolic disturbances that increase fracture risk. Although metformin (MET) is used traditionally as first-line treatment for type 2 diabetes (T2DM), its effectiveness in completely reversing diabetic bone homeostasis is uncertain. The present study was conducted to assess the short-term effect of MET on alveolar bone histological structure and osteoblastic gene expression in rats with streptozotocin (STZ)-induced type 2 diabetes mellitus (T2DM). Methods Eighteen adult male Wistar rats were divided equally into three groups (n = 6/group): control group (non-diabetic) was injected with saline, STZ group (diabetic) received 10% fructose solution for 2 weeks followed by an injection of a single dose of STZ (40 mg/kg), and MET group (diabetic with MET-treatment) received 100 mg/kg/day MET for 30 days. Alveolar bone was assessed by histological and histomorphometric analysis, cone beam computed tomography (CBCT), and reverse transcription-polymerase chain reaction (RT-PCR) analysis of bone-related gene expression. Results The STZ group showed pronounced decreases in total bone area, osteoblast area, and bone-related gene expression (RunX2, osteocalcin, COL1A1) compared to the control group. MET significantly improved these parameters compared to the STZ group. Conclusions Metformin significantly increased total bone area and osteoblastic gene expression (Runx2, osteocalcin, and COL1A1) compared to untreated diabetic rats but did not fully restore them to control (non-diabetic) levels. These results suggest a partial protective effect of metformin in alveolar bone in this short-term T2DM rat model.
SN - 1472-6831
ER -